Enzon to Begin Phase 1 Study of Novel Androgen Receptor mRNA Antagonist in Castration-Resistant Prostate Cancer.
Business Wire › January 10, 2011
Linked as:
Extract
Enzon to Begin Phase 1 Study of Novel Androgen Receptor mRNA Antagonist in Castration-Resistant Prostate Cancer.
BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evalua...
See the full content of this document
Sponsored links
